MRNA
VENTE TOTALE: 499 246 titres (~28 062 617,66 $ US)
- Insiders
- Bancel Stephane
- Total bought
- —
- Total sold
- $28,062,618
- Last activity
- 2026-08-05
- Last synced
-
2026-08-11 09:46:50
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-09-06
MRNA presents a classic high-risk event-driven setup: a strong catalyst (FDA mFlusiva approval + earnings beat narrative) with a solid catalyst confidence of 0.75 drives near-term momentum, but the deeply negative…
The first sentence of the analysis written for MRNA on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 55.3% | 54.2% | 31.5% | 71.3% | 85.2% | |
| Ebit Margin | -142.4% | -112.0% | -57.0% | 50.9% | 75.0% | |
| Ebitda Margin | -131.3% | -106.1% | -47.9% | 52.7% | 76.3% | |
| Operating Profit Margin | -158.1% | -123.3% | -61.9% | 49.9% | 75.0% | |
| Pretax Profit Margin | -142.4% | -112.8% | -57.6% | 50.7% | 74.9% | |
| Continuous Operations Profit Margin | -145.2% | -111.3% | -68.8% | 44.3% | 68.8% | |
| Net Profit Margin | -145.2% | -111.3% | -68.8% | 44.3% | 68.8% | |
| Bottom Line Profit Margin | -145.2% | -111.3% | -68.8% | 44.3% | 68.8% | |
| Current Ratio | 3.293 | 3.671 | 3.425 | 2.728 | 1.761 | |
| Quick Ratio | 3.216 | 3.618 | 3.358 | 2.535 | 1.603 | |
| Solvency Ratio | -0.707 | -1.040 | -0.895 | 1.293 | 1.181 | |
| Cash Ratio | 1.306 | 0.874 | 0.964 | 0.651 | 0.750 | |
| Price To Earnings Ratio | -4.062 | -4.485 | -8.059 | 8.449 | 8.379 | |
| Price To Earnings Growth Ratio | 0.187 | 0.180 | 0.051 | -0.283 | -0.005 | |
| Forward Price To Earnings Growth Ratio | 0.187 | 0.180 | 0.051 | -0.283 | -0.005 | |
| Price To Earnings Diluted Ratio | -4.062 | -4.485 | -8.059 | 8.936 | 8.978 | |
| Price To Earnings Diluted Growth Ratio | 0.187 | 0.180 | 0.050 | -0.309 | -0.006 | |
| Price To Book Ratio | 1.326 | 1.465 | 2.742 | 3.701 | 7.236 | |
| Price To Sales Ratio | 5.901 | 4.991 | 5.548 | 3.749 | 5.771 | |
| Price To Free Cash Flow Ratio | -5.555 | -3.938 | -9.932 | 15.449 | 7.675 | |
| Price To Operating Cash Flow Ratio | -6.125 | -5.315 | -12.184 | 14.208 | 7.515 | |
| Debt To Assets Ratio | 0.155 | 0.053 | 0.067 | 0.046 | 0.037 | |
| Debt To Equity Ratio | 0.222 | 0.069 | 0.090 | 0.063 | 0.065 | |
| Debt To Capital Ratio | 0.181 | 0.064 | 0.082 | 0.059 | 0.061 | |
| Long Term Debt To Capital Ratio | 0.126 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.426 | 1.297 | 1.330 | 1.352 | 1.744 | |
| Working Capital Turnover Ratio | 0.372 | 0.485 | 0.866 | 2.443 | 4.007 | |
| Operating Cash Flow Ratio | -0.943 | -1.362 | -1.034 | 1.012 | 1.492 | |
| Operating Cash Flow Sales Ratio | -0.963 | -0.939 | -0.455 | 0.264 | 0.768 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.103 | 1.350 | 1.227 | 0.920 | 0.979 | |
| Debt Service Coverage Ratio | -260.700 | -139.500 | -106.711 | 301.345 | 691.778 | |
| Interest Coverage Ratio | -307.400 | -164.375 | -111.553 | 324.828 | 738.667 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.978 | -4.021 | -2.508 | 4.151 | 14.869 | |
| Capital Expenditure Coverage Ratio | -9.755 | -2.858 | -4.410 | 12.453 | 47.958 | |
| Dividend Paid And Capex Coverage Ratio | -9.755 | -2.858 | -4.410 | 12.453 | 47.958 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -4.227 | -4.357 | -11.065 | 6.910 | 7.124 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 55.4% | ▲1.1% | ▼-4.2% |
| Ebit Margin | -142.4% | ▼-30.4% | ▼-105.3% |
| Ebitda Margin | -131.3% | ▼-25.2% | ▼-100.1% |
| Operating Profit Margin | -158.1% | ▼-34.8% | ▼-114.4% |
| Pretax Profit Margin | -142.4% | ▼-29.6% | ▼-105.0% |
| Continuous Operations Profit Margin | -145.2% | ▼-33.9% | ▼-102.7% |
| Net Profit Margin | -145.2% | ▼-33.9% | ▼-102.7% |
| Bottom Line Profit Margin | -145.2% | ▼-33.9% | ▼-102.7% |
| Current Ratio | 3.293 | ▼-0.378 | ▲0.318 |
| Quick Ratio | 3.216 | ▼-0.402 | ▲0.350 |
| Solvency Ratio | -0.707 | ▲0.334 | ▼-0.673 |
| Cash Ratio | 1.306 | ▲0.432 | ▲0.397 |
| Price To Earnings Ratio | -4.062 | ▲0.423 | ▼-4.106 |
| Price To Earnings Growth Ratio | 0.187 | ▲0.007 | ▲0.161 |
| Forward Price To Earnings Growth Ratio | 0.187 | ▲0.007 | ▲0.161 |
| Price To Earnings Diluted Ratio | -4.062 | ▲0.423 | ▼-4.324 |
| Price To Earnings Diluted Growth Ratio | 0.187 | ▲0.007 | ▲0.167 |
| Price To Book Ratio | 1.326 | ▼-0.139 | ▼-1.968 |
| Price To Sales Ratio | 5.901 | ▲0.910 | ▲0.709 |
| Price To Free Cash Flow Ratio | -5.555 | ▼-1.618 | ▼-6.295 |
| Price To Operating Cash Flow Ratio | -6.125 | ▼-0.810 | ▼-5.745 |
| Debt To Assets Ratio | 0.155 | ▲0.102 | ▲0.084 |
| Debt To Equity Ratio | 0.222 | ▲0.153 | ▲0.120 |
| Debt To Capital Ratio | 0.181 | ▲0.117 | ▲0.092 |
| Long Term Debt To Capital Ratio | 0.126 | ▲0.126 | ▲0.101 |
| Financial Leverage Ratio | 1.426 | ▲0.129 | ▼-0.004 |
| Working Capital Turnover Ratio | 0.372 | ▼-0.113 | ▼-1.262 |
| Operating Cash Flow Ratio | -0.943 | ▲0.419 | ▼-0.776 |
| Operating Cash Flow Sales Ratio | -0.964 | ▼-0.024 | ▼-0.698 |
| Free Cash Flow Operating Cash Flow Ratio | 1.103 | ▼-0.247 | ▼-0.013 |
| Debt Service Coverage Ratio | -260.700 | ▼-121.200 | ▼-357.942 |
| Interest Coverage Ratio | -307.400 | ▼-143.025 | ▼-403.433 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -0.978 | ▲3.044 | ▼-3.280 |
| Capital Expenditure Coverage Ratio | -9.755 | ▼-6.897 | ▼-18.433 |
| Dividend Paid And Capex Coverage Ratio | -9.755 | ▼-6.897 | ▼-18.433 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -4.227 | ▲0.129 | ▼-3.104 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $11.47B | $15.97B | $37.99B | $70.77B | $102.35B | |
| Enterprise value | $10.79B | $14.79B | $36.33B | $68.77B | $96.42B | |
| EV / Sales | 5.55x | 4.62x | 5.30x | 3.64x | 5.44x | |
| EV / Op. cash flow | -5.76x | -4.92x | -11.65x | 13.81x | 7.08x | |
| EV / Free cash flow | -5.23x | -3.65x | -9.50x | 15.01x | 7.23x | |
| EV / EBITDA | -4.23x | -4.36x | -11.06x | 6.91x | 7.12x | |
| Net debt / EBITDA | 0.27x | 0.35x | 0.51x | -0.20x | -0.44x | |
| Current ratio | 3.29x | 3.67x | 3.42x | 2.73x | 1.76x | |
| Income quality | 0.66x | 0.84x | 0.66x | 0.60x | 1.12x | |
| Graham number | — | — | — | $152 | $155 | |
| Graham net-net | $6 | $11 | $13 | $12 | $8 | |
| Tax burden | 102.0% | 98.7% | 119.6% | 87.3% | 91.8% | |
| Interest burden | 100.0% | 100.7% | 101.0% | 99.7% | 99.9% | |
| Working capital | $4.56B | $5.89B | $7.31B | $8.51B | $6.94B | |
| Invested capital | $7.51B | $8.94B | $10.06B | $10.65B | $8.33B | |
| Return on assets | -22.9% | -25.2% | -25.6% | 32.3% | 49.5% | |
| Operating ROA | -23.2% | -24.2% | -19.1% | 37.3% | 83.1% | |
| Return on tangible assets | -23.1% | -25.3% | -25.7% | 32.3% | 49.5% | |
| Return on equity | -32.6% | -32.7% | -34.0% | 43.7% | 86.3% | |
| Return on invested capital | -29.7% | -32.5% | -27.5% | 38.9% | 77.5% | |
| Return on capital employed | -29.7% | -33.1% | -27.5% | 45.0% | 85.6% | |
| Earnings yield | -24.6% | -22.3% | -12.4% | 11.8% | 11.9% | |
| Free cash flow yield | -18.0% | -25.4% | -10.1% | 6.5% | 13.0% | |
| Capex / Op. cash flow | -10.3% | -35.0% | -22.7% | 8.0% | 2.1% | |
| Capex / Depreciation | 89.3% | 556.1% | 113.8% | 114.9% | 122.4% | |
| Capex / Sales | 9.9% | 32.9% | 10.3% | 2.1% | 1.6% | |
| SG&A / Sales | 52.4% | 36.7% | 22.6% | 6.0% | 3.2% | |
| R&D / Sales | 161.1% | 142.0% | 70.8% | 17.5% | 11.2% | |
| Stock comp / Sales | 24.8% | 13.4% | 4.5% | 1.2% | 0.8% | |
| Intangibles / Total assets | 0.8% | 0.7% | 0.5% | 0.0% | 0.0% | |
| Days sales outstanding | 53d | 68d | 58d | 33d | 68d | |
| Days payables outstanding | 133d | 101d | 40d | 33d | 42d | |
| Operating cycle | 118d | 97d | 73d | 97d | 269d | |
| Cash conversion cycle | -16d | -4d | 33d | 64d | 227d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-28.2%EV / Sales ▲+20.1%EV / EBITDA ▲+3.0%EV / Op. cash flow ▼-0.840Earnings yield ▼-0.023
Profitability
Return on equity +0.000Return on assets ▲+0.023Return on invested capital ▲+0.028Return on capital employed ▲+0.034Operating ROA ▲+0.010Income quality ▼-0.180Tax burden ▲+0.032
Efficiency
Days sales outstanding ▼-14.223Days payables outstanding ▲+32.327Operating cycle ▲+20.944Cash conversion cycle ▼-11.383Capex / Sales ▼-0.230R&D / Sales ▲+0.191
Balance-sheet strength
Current ratio ▼-0.378Net debt / EBITDA ▼-0.082Working capital ▼-1336000000.000Invested capital ▼-1433000000.000Intangibles / Total assets ▲+0.001
Change over 5 years
Valuation
Market cap ▼-88.8%EV / Sales ▲+2.1%EV / EBITDA ▼-159.3%EV / Op. cash flow ▼-12.842Earnings yield ▼-0.365
Profitability
Return on equity ▼-1.189Return on assets ▼-0.723Return on invested capital ▼-1.072Return on capital employed ▼-1.153Operating ROA ▼-1.063Income quality ▼-0.452Tax burden ▲+0.101
Efficiency
Days sales outstanding ▼-15.063Days payables outstanding ▲+91.180Operating cycle ▼-151.706Cash conversion cycle ▼-242.886Capex / Sales ▲+0.083R&D / Sales ▲+1.499
Balance-sheet strength
Current ratio ▲+1.533Net debt / EBITDA ▲+0.704Working capital ▼-2386000000.000Invested capital ▼-819000000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-01-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-08-26 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-07-25 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-04-08 | Rob Bresnahan | Sale (Full) | $1,001 - $15,000 |
| 2025-02-25 | Rob Bresnahan | Purchase | $1,001 - $15,000 |
| 2025-01-15 | Julie Johnson | Sale (Full) | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-03-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-02-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-02-01 | Josh Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2024-01-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-09-15 | Josh Gottheimer | Sale | $1,001 - $15,000 |
| 2023-08-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-08-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-07-28 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-07-12 | Daniel Goldman | Sale | $50,001 - $100,000 |
| 2023-06-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-19 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-04-25 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-04-10 | Daniel Goldman | Purchase | $50,001 - $100,000 |
| 2023-03-31 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-03-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-03-06 | Daniel Goldman | Sale (Full) | $50,001 - $100,000 |
| 2023-02-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-11-02 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-09-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-01 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-06-27 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-06-16 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-05 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-04-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-04-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-03-16 | Josh Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-02-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-21 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-01-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2021-07-22 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2021-03-15 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2021-01-29 | Marie Newman | Sale (Full) | $15,001 - $50,000 |
| 2021-01-29 | Marie Newman | Sale (Full) | $1,001 - $15,000 |
| 2020-05-22 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
Recent news
- 2026-08-10 Moderna, Inc. $MRNA Shares Acquired by Contravisory Investment Management Inc. Contravisory Investment Management Inc. increased its position in shares of Moderna, Inc. (NASDAQ: MRNA) by 1,387.6% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 24,218 shares of the company''s stock after purchasing an additional 22,590 shares during the quarter. Contravisory Investment
- 2026-08-07 Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones MRNA keeps its 2026 growth target intact while cutting cost guidance and advancing flu, oncology and rare-disease programs toward key milestones.
- 2026-08-07 These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.
- 2026-08-06 This new kind of flu shot by Moderna has just been approved by the FDA The Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic, said the manufacturer, Moderna.The shot, named mFlusiva, is intended for adults who are 50 and older. Other brands of flu shots already have begun arriving in pharmacies ahead of fall vaccination season, and Moderna said late Wednesday that it expects some of its new version to be available soon at select retailers.While there already are multiple flu vaccine options in the U.S., including three specifically recommended for people age 65 or older, tens of thousands of Americans die from influenza every year and older adults are among the most vulnerable.Flu vaccines must be updated annually to best match circulating strains of the virus.
- 2026-08-06 Moderna Stock Flashing Intriguing ‘Buy The Dip'' Signal Moderna (MRNA) stock made a name for itself during the height of the pandemic, trading as high as $497 five years ago in 2021. Now, shares of the drugmaker sit at $55.12, pivoting lower despite the Food and Drug Administration (FDA) approving the company''s flu vaccine.
- 2026-08-06 Beyond COVID: Moderna Wins FDA Approval for Its Seasonal Flu Vaccine The U.S. Food and Drug Administration (FDA) on Wednesday approved Moderna Inc.''s (NASDAQ:MRNA) mFLUSIVA (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older.
- 2026-08-06 Moderna Stock Climbs on Flu Vaccine Approval Moderna Inc (NASDAQ:MRNA) is up 3.6% at $58.30 ahead of the open, after the U.S. Food and Drug Administration (FDA) approved the company''s mRNA-based seasonal flu vaccine , mFluvis, for adults ages 50 and older.
- 2026-08-06 Moderna Stock Rises as Flu Vaccine Approval Offers Spark for a Post-Pandemic Future Moderna''s mRNA-based flu vaccine, mFlusiva, is approved by the Food and Drug Administration for adults aged 50 and over.
- 2026-08-06 Sandisk, AppLovin, Moderna, and More Stocks That Explain Today''s Market Memory stocks falter after guidance from Sandisk and Western Digital fails to meet the market''s sky-high expectations.
- 2026-08-06 FDA Approves First mRNA Flu Vaccine For Older Adults "Flu remains a significant public health challenge, and mFLUSIVA provides an important new option for America''s seniors. This approval also reflects the ongoing potential of our mRNA platform,” Moderna CEO Stéphane Bancel said.